Non-mydriatic multicolour imaging

Article

The latest advancement in optical imaging.

The latest advance in optical imaging is the addition of multicolour imaging to OCT cameras. I have experienced this technological advancement with Heidelberg Engineering's MultiColor technology for SPECTRALIS, which allows simultaneous scanning with three selective coloured lasers: infrared, green and blue. In this article, I will outline the basis of multicolour imaging, highlighting advantages and revealing my experiences.

Background to the MultiColor

Benefits across a range of diseases

One of the great benefits of OCT imaging is that it is non-invasive and non-mydriatic. The new SPECTRALIS models allow the user to capture an OCT image and at the same time a colour image that is very similar to a fundus image, without having to dilate the patient. Because the lasers are continually scanning, a live fundus image is delivered that makes camera alignment very easy. Moreover, the confocal optic suppresses scattered light and produces high contrast images, even in many patients with cataract. In my opinion, MultiColor images are excellent educational tools for the patient as they are much easier to understand than infrared images.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.